MTOR and urinary bladder carcinoma: Currently, everolimus is the only mTOR inhibitor approved by the U.S. Food and Drug Administration to treat breast cancer, advanced renal carcinoma, pancreatic neuroendocrine tumor and subependymal giant-cell astrocytoma, thus opening this therapeutic approach for bladder carcinoma as well [6].